Cyclacel Pharmaceuticals Inc 6 % Conv Pfd Shs

Cyclacel Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company. It uses cell cycle, transcriptional regulation and DNA damage response biology to develop medicines for cancer and other proliferative diseases. The company builds a biopharmaceutical business, which is focused in hematology and oncology based on a pipeline of novel drug candidates. Its products include CYC065, seliciclib, and sapacitabine. The company was founded by Ronald J. Berenson, David Philip Lane, and David Glover on August 13, 1996 and is headquartered in Berkeley Heights, NJ.

Cyclacel Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in the provision of cell cycle, transcriptional regulation and DNA damage response biology to develop medicines for cancer and other proliferative diseases. It operates through the United States and United Kingdom geographical segments. The company builds a biopharmaceutical business, which is focused on hematology and oncology based on a pipeline of novel drug candidates. Its products include CYC065, seliciclib, and sapacitabine. The company was founded by Ronald J. Berenson, David Philip Lane, and David Glover on August 13, 1996 and is headquartered in Berkeley Heights, NJ.

Cyclacel Pharmaceuticals

BERKELEY HEIGHTS, N.J., Nov. 03, 2022 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, will announce third quarter 2022 financial results on Wednesday, November 9, 2022. The company will host a conference call and live webcast at 4:30 p.m. Eastern Time on the same day.

Cyclacel Pharmaceuticals to Release Third Quarter 2022 Financial Results

Daily dosing of fadraciclib was well tolerated; single agent activity observed across multiple tumor types including 2 PRs in T-cell lymphoma patients Daily dosing of fadraciclib was well tolerated; single agent activity observed across multiple tumor types including 2 PRs in T-cell lymphoma patients

Cyclacel Reports Preliminary Data From Its Phase 1/2 Clinical Trial of Oral Fadraciclib in Patients With Solid Tumors and Lymphoma at ENA 2022

-Program Update on its CDK2/9 Inhibitor, Oral Fadraciclib, and Oral PLK1 Inhibitor, CYC140, for the Treatment of Advanced Solid Tumors and Lymphoma-

Cyclacel Hosting Research & Development Day

- Preliminary Dose Escalation Data to be Presented on Novel CDK2/9 Inhibitor Fadraciclib in Patients with Solid Tumors and Lymphoma - - Preliminary Dose Escalation Data to be Presented on Novel CDK2/9 Inhibitor Fadraciclib in Patients with Solid Tumors and Lymphoma -

Cyclacel Pharmaceuticals To Present Preliminary Data From The Phase 1/2 Clinical Trial Of Oral Fadraciclib At The 34th EORTC-NCI-AACR Symposium

BERKELEY HEIGHTS, N.J., Sept. 21, 2022 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, today announced that management will participate in Ladenburg Thalmann's 2022 Healthcare Conference on September 29, 2022 at the Sofitel New York.

Cyclacel Pharmaceuticals to Present at the Ladenburg Thalmann 2022 Healthcare Conference

Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC ) Q2 2022 Earnings Conference Call August 10, 2022 4:30 PM ET Company Participants Irina Koffler - LifeSci Advisors Spiro Rombotis - President and Chief Executive Officer Paul McBarron - Executive Vice President, Chief Financial Officer and Chief Operating Officer Mark Kirschbaum - Senior Vice President and Chief Medical Officer Conference Call Participants Ahu Demir - Ladenburg Thalmann & Co Jonathan Aschoff - ROTH Capital Partners Operator Good afternoon, and welcome to the Cyclacel Pharmaceuticals Second Quarter 2022 Results Conference Call and Webcast. [Operator Instructions].

Cyclacel Pharmaceuticals, Inc. (CYCC) CEO Spiro Rombotis on Q2 2022 Results - Earnings Call Transcript

- Oral fadraciclib demonstrated good tolerability with continuous dosing;  anticipate entering Phase 2 POC stage in 2H 2022 –

Cyclacel Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Business Update

BERKELEY HEIGHTS, N.J., Aug. 03, 2022 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, will announce second quarter 2022 financial results on Wednesday, August 10, 2022. The company will host a conference call and live webcast at 4:30 p.m. Eastern Daylight Time on the same day.

Cyclacel Pharmaceuticals to Release Second Quarter 2022 Financial Results

- Completed Enrollment in Phase 1 Dose Escalation with Oral Fadraciclib in Solid Tumors -

Cyclacel Pharmaceuticals Achieves Key Business Objectives in First Half of 2022 and Continues to Advance Clinical Pipeline

BERKELEY HEIGHTS, N.J., June 22, 2022 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, today announced the election of Kenneth M. Ferguson, Ph.D., to its Board of Directors. Dr. Ferguson was elected by and will represent the 6% Convertible Exchangeable Preferred stockholders.

Cyclacel Pharmaceuticals Announces That Kenneth M. Ferguson, Ph.D.

Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC ) Q1 2022 Earnings Conference Call May 11, 2022 4:30 PM ET Company Participants Irina Koffler - LifeSci Advisors Spiro Rombotis - President, CEO & Executive Director Paul McBarron - EVP, CFO, COO, Secretary & Executive Director Mark Kirschbaum - SVP & Chief Medical Officer Conference Call Participants Kevin DeGeeter - Oppenheimer Ahu Demir - Ladenburg Thalmann & Co. Jonathan Aschoff - ROTH Capital Partners Operator Good afternoon, and welcome to the Cyclacel Pharmaceuticals First Quarter 2022 Results Conference Call and Webcast. [Operator Instructions].

Cyclacel Pharmaceuticals, Inc. (CYCC) CEO Spiro Rombotis on Q1 2022 Results - Earnings Call Transcript

BERKELEY HEIGHTS, N.J., May 04, 2022 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, will announce first quarter 2022 financial results on Wednesday, May 11, 2022. The company will host a conference call and live webcast at 4:30 p.m. Eastern Daylight Time on the same day.

Cyclacel Pharmaceuticals to Release First Quarter 2022 Financial Results

- CYC140, a Potent and Selective PLK1 Inhibitor to Be Evaluated as a Single Agent Across Multiple Solid Tumor and Lymphoma Types in Streamlined, Registration-Directed Study - - CYC140, a Potent and Selective PLK1 Inhibitor to Be Evaluated as a Single Agent Across Multiple Solid Tumor and Lymphoma Types in Streamlined, Registration-Directed Study -

Cyclacel Announces Dosing of First Patient in Phase 1/2 Study of Oral Cyc140 in Patients With Advanced Solid Tumors and Lymphomas

-New Preclinical Data Highlight Fadraciclib's Apoptosis Enabling Mechanism in Leukemia-

Cyclacel Pharmaceuticals Announces Publication Confirming Fadraciclib Suppresses MCL1 and Synergizes With Venetoclax in Chronic Lymphocytic Leukemia

Cyclacel Pharmaceuticals, Inc. (CYCC) CEO Spiro Rombotis on Q4 2021 Results - Earnings Call Transcript

-Initial Data from Phase 1/2 Study of Oral Fadraciclib in Solid Tumors Expected in First Half of 2022 –

Cyclacel Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results

BERKELEY HEIGHTS, N.J., March 22, 2022 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, will announce fourth quarter and full year 2021 financial results on Monday, March 28, 2022. The company will host a conference call and live webcast at 4:30 p.m. Eastern Daylight Time on the same day.

Cyclacel Pharmaceuticals to Release Fourth Quarter and Full Year 2021 Financial Results

BERKELEY HEIGHTS, N.J., Feb. 07, 2022 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, today announced that the Company will participate in the 2022 BIO CEO & Investor Conference on February 14-17, 2022.

Cyclacel Pharmaceuticals to Participate in 2022 BIO CEO & Investor Conference

– Now Enrolling Patients in Two Registration-Directed Trials for Lead Candidate, Oral Fadraciclib –

Cyclacel Pharmaceuticals Reviews 2021 Achievements And Announces Key Business Objectives for 2022

BERKELEY HEIGHTS, N.J., Dec. 23, 2021 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, today announced that the Company will participate in the Biotech Showcase 2022 Virtual Conference to be held January 10-12, 2022. Spiro Rombotis, President & Chief Executive Officer, will present an overview of Cyclacel's business and the Company will be available for virtual meetings during the conference. In addition, Mr. Rombotis will participate in a Biotech Showcase Workshop, entitled, “Outsmarting Cancer: Next Generation Therapies”.

Cyclacel Pharmaceuticals to Participate in Biotech Showcase 2022 Virtual Conference

Cyclacel Pharmaceuticals, Inc. (CYCC) CEO Spiro Rombotis on Q3 2021 Results - Earnings Call Transcript

Next-Generation CDK2/9 Inhibitor Fadraciclib to Be Evaluated as a Single Agent and in Combinations in Streamlined, Registration-Directed Study Next-Generation CDK2/9 Inhibitor Fadraciclib to Be Evaluated as a Single Agent and in Combinations in Streamlined, Registration-Directed Study

Cyclacel Announces Dosing of First Patient in Phase 1/2 Study of Oral Fadraciclib in Patients With Leukemias or Myelodysplastic Syndromes

BERKELEY HEIGHTS, N.J., Oct. 29, 2021 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, will announce third quarter financial results and provide a business update on Wednesday, November 10, 2021. The company will host a conference call and live webcast at 4:30 p.m. Eastern Daylight Time on the same day.

Cyclacel Pharmaceuticals to Release Third Quarter 2021 Financial Results and Provide Business Update

BERKELEY HEIGHTS, N.J., Sept. 08, 2021 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, today announced that the Company will participate in three investor conferences in September.

Cyclacel Pharmaceuticals Presenting at Three Conferences in September

Cyclacel Pharmaceuticals, Inc. (CYCC) CEO Spiro Rombotis on Q2 2021 Results - Earnings Call Transcript

News for Cyclacel Pharmaceuticals Inc 6 % Conv Pfd Shs Stock (CYCCP)